PC
The company develops precision oncology therapeutics that target DNA Damage Repair (DDR) pathways to enhance anti-tumor immunity. By discovering small molecule modulators, it provides patients with new treatment options for cancer and related diseases.
Updated 4 months ago
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The company develops precision oncology therapeutics that target DNA Damage Repair (DDR) pathways to enhance anti-tumor immunity. By discovering small molecule modulators, it provides patients with new treatment options for cancer and related diseases.